Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease

Virginie F. Viprey and Susan A. Burchill
Virginie F. Viprey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan A. Burchill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-09-1601 Published November 2009
  • Article
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Correction: Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease - April 28, 2010

To the Editor: As Cheung et al. (1) report, accurate assessment of minimal disease is essential to inform the fight to cure children with neuroblastoma. Cheung et al. have exploited gene expression profiling to identify and prioritize targets for the detection of this disease using quantitative reverse transcriptase-PCR (RT-PCR). Eight of 34 genes are prioritized for investigation.

Using a similar approach, we and others have previously identified three key mRNA targets (2); one of these targets (Phox2B) has also been prioritized by Cheung et al. Interestingly, the sensitivity and specificity of Phox2B as a target for the detection of minimal disease by quantitative RT-PCR in children with neuroblastoma has been corroborated (3, 4). However, differences in the remaining putative targets for optimal detection of minimal disease may lead to skepticism about the value of genome-wide expression data to inform candidate selection. Unfortunately, a direct comparison of data from the two Affymetrix array minimal disease studies in neuroblastoma (1, 2) is limited due to several differences in methods. First, the study of Cheung et al. (1) used the Affymetrix human U95 platform, in contrast to the U133 Plus 2.0 array used in our study (2). Using the U95 platform, Cheung et al. identified MEG3 and MLLT11 as specific sequences, although these probe sets also match to an additional five and two potential targets, respectively. This reinforces the importance of careful verification of probe-set gene annotation (2). Cheung et al. (1) report that they have excluded targets known to be expressed in bone marrow from healthy volunteers, although they do not describe the steps taken to identify such genes. Searching the National Center for Biotechnology Information expressed sequence tag database for the 34 potential markers of minimal disease identified by Cheung et al., we found that six of these genes have previously been described in bone marrow (CCND1, KIF21A, MLLT11, PFN2, UCHL1, and MAOA) and 11 in peripheral blood (CCND1, KIF21A, MLLT11, PFN2, KIF5C, MEG3, GRIA2, DDC, RGS5, KIF1A, and GABRB3) from healthy volunteers. Not surprisingly then, all but DDC were subsequently detected in normal blood using quantitative RT-PCR (1). The selection of eight targets for detection of minimal disease by Cheung et al. (1) is therefore questionable. The precision of minimal disease detection using quantitative RT-PCR will be facilitated by standardized assays for selected candidate genes not expressed in the normal hemopoietic compartments (2, 5).

The clinical significance of minimal disease detected by quantitative RT-PCR for individual mRNAs emphasizes the importance of this disease and the studies by Cheung et al. (1), although it is unfortunate that they did not investigate the independent prognostic significance of detecting disease using individual and multiple marker sets (4).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

  1. ↵
    1. Cheung IY,
    2. Feng Y,
    3. Gerald W,
    4. Cheung NV
    . Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 2008;14:7020–27.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Viprey VF,
    2. Lastowska MA,
    3. Corrias MV,
    4. Swerts K,
    5. Jackson MS,
    6. Burchill SA
    . Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 2008;216:245–52.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Stutterheim J,
    2. Gerritsen A,
    3. Zappeij-Kannegieter L,
    4. et al
    . Phox2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008;26:5443–9.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Stutterheim J,
    2. Gerritsen A,
    3. Zappeij-Kannegieter L,
    4. et al
    . Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem 2009;55:1316.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Viprey VF,
    2. Corrias MV,
    3. Kagedal B,
    4. et al
    . Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer 2007:341–50.
PreviousNext
Back to top
Clinical Cancer Research: 15 (21)
November 2009
Volume 15, Issue 21
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease
Virginie F. Viprey and Susan A. Burchill
Clin Cancer Res November 1 2009 (15) (21) 6742; DOI: 10.1158/1078-0432.CCR-09-1601

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease
Virginie F. Viprey and Susan A. Burchill
Clin Cancer Res November 1 2009 (15) (21) 6742; DOI: 10.1158/1078-0432.CCR-09-1601
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Letter
  • Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Response
  • Plasma Tumor Mutation Burden and Response to Pembrolizumab—Response
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement